Who is sponsoring NCT00289614?

NCT00289614 is sponsored by Bracco Diagnostics, Inc.

What condition does NCT00289614 study?

NCT00289614 studies Kidney Diseases.

What drugs are being tested in NCT00289614?

Interventions: Iopamidol 370 mgI/dL.

What is the status of NCT00289614?

NCT00289614 is currently COMPLETED.

Last reviewed 2008-01-03 · How we verify

Patients With Renal Impairment and Diabetes Undergoing Computed Tomography

NCT00289614 Phase 4 COMPLETED

The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment undergoing clinically indicated contrast enhanced multidetector computed tomography (MDCT). Serum creatinine will be measured before and up to 48-72 hours post dose.

Details

Lead sponsor	Bracco Diagnostics, Inc
Phase	Phase 4
Status	COMPLETED
Enrolment	350
Start date	2006-01
Completion	2007-04

Conditions

Kidney Diseases

Interventions

Iopamidol 370 mgI/dL

Primary outcomes

Increase in serum creatinine (SCr) at 48-72 hours post dose

Countries

United States